Jazz reports lower quarterly Epidiolex sales but growth across nine months, while a proposed CBD capsule awaits an FDA decision targeted for April 2027.
Idaho votes November 3 on who can legalize cannabis. Here is what HJR 4 would change—and why neither outcome immediately legalizes marijuana.
The Mount Dora gathering pairs live music with cannabis-focused exhibitors, while admission and Florida’s medical program remain separate matters.
Sunday’s results delivered a debut victory, a returning champion and a close American podium finish. CBD’s place in sport remains a separate question.
The hemp label’s London fair appearance puts fabric weight, fit and everyday wear ahead of cannabis-themed graphics.
The physicians’ organization wants botanical products evaluated through rigorous evidence as FDA gathers feedback on research, manufacturing and regulatory challenges.
The Santa Monica label’s founder is looking for support to bring core styles back into production, with no completed deal or relaunch date announced.
A newly published survey points to an education and communication problem around cannabinoids, while its methods place clear limits on broad claims about athletes.
Federal registration is moving forward for qualifying medical dispensaries, but the new guidance reaches beyond the storefront to suppliers, records and laboratory testing.
The Detroit label’s November launch puts hemp fabric, local production and the details of everyday clothing at the center of cannabis-connected fashion.